シンポジウム19：片頭痛治療最前線―新規治療update2020
5–HT1F作動薬ditan：作用機序とtriptanとの棲み分け
2021 年 38 巻 4 号 p. 648-651
詳細
2021 年 38 巻 4 号 p. 648-651
Triptan, a class of serotonin 5–HT1B/1D receptor agonists, are currently the first choice for acute migraine treatment. Triptans cause vasoconstriction by activation of 5–HT1B receptors, and are contraindicated in patients with certain cardiovascular conditions and events. Lasmiditan is a selective 5–HT1F agonist, so called ditan, without causing vasoconstriction. Lasmiditan was approved by the U.S. Food and Drug Administration (FDA) on October 11, 2019, and is the only ditan currently in clinical use. This article reviews both preclinical and clinical studies on lasmiditan as a potential acute therapy for migraine, as well as pharmacokinetic and pharmacodynamic features.
